HCM
TPST icon

Highbridge Capital Management’s Tempest Therapeutics TPST Stock Holding History

Highbridge Capital Management’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-27
Closed -$679K – 1812
2015
Q3 		$679K Buy
27
+10
+59% +$673K 0.01% 914
2015
Q2 		$1.45M Buy
+17
New +$1.56M 0.02% 616

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CC
CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Highbridge Capital Management's TPST Position: Q4 2016 in Review

Highbridge Capital Management sold out of Tempest Therapeutics (TPST) in Q4 2016, closing a stake of 17 shares — an estimated $350K sold.

Highbridge Capital Management first reported a position in TPST in Q4 2014 and held it in 5 quarters. The position peaked at $8.36M in Q4 2014. 84 funds tracked by Wall St. Rank hold TPST as of Q4 2016.

  • Highbridge Capital Management reported no remaining Tempest Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 17 Tempest Therapeutics shares in Q4 2016, an estimated $350K.
  • Highbridge Capital Management first reported a position in Tempest Therapeutics in Q4 2014 and held it in 5 quarters.
  • Highbridge Capital Management's Tempest Therapeutics position peaked at $8.36M in Q4 2014.
  • 84 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.